dacarbazine,pegfilgrastim,doxorubicin,nivolumab,brentuximab vedotin,vinblastine,filgrastim
amgen,bms,seagen
[]
 i agree, i think the future prospective about adapting which is more about the economical value of having n-avd or dd abvd and long term outcome/safety which will be interesting to have!
Hematology/BMT Clinical Pharmacist @KFMC_Riyadh. Senior Lecturer @Alfaisaluniv. (still)Coffeeholic. 

يا رب انك تجمعنا بوالدي في جناتك